FMS样酪氨酸激酶3在恶性肿瘤中的研究进展

Research progress of FMS-like tyrosine kinase-3 in malignancies

FMS样酪氨酸激酶3(FLT3)改变在血液系统及非血液系统恶性肿瘤中均有发现。血液系统疾病研究多集中于伴FLT3突变的急性髓系白血病,FLT3突变通过激活信号传导和转录激活因子5、蛋白激酶B等通路,促进白血病的发生发展。在实体肿瘤中也有研究发现FLT3存在一定作用,如FLT3表达在肝癌发生及侵袭过程起关键作用。因此,FLT3可以成为肿瘤有前景的治疗靶点。

FMS-like tyrosine kinase-3(FLT3) alteration has been discovered in many malignancies. In the field of hematological diseases,most studies focus on acute myeloid leukemia with FLT3 mutation. FLT3 mutation promotes the occurrence and development of leukemia by activating signal transducer and activator of transcription and protein kinase B pathways. FLT3 expression has been found to play a role in solid tumors,such as in the occurrence and invasion of hepatocellular carcinoma. FLT3 becomes a promising target in the treatment of tumors.